ArticleCureus2025
Dyslipidemia Associated With Type 2 Diabetes Mellitus as a Strong Predictor of ICU Admission in COVID-19 Patients: A Retrospective Comparative Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe global COVID-19 pandemic has raised questions about the complex interplay between chronic non-communicable diseases and the clinical trajectory of the disease. Among these, dyslipidemia and type 2 diabetes mellitus (T2DM) have emerged as significant contributors to adverse COVID-19 outcomes and intensive care unit (ICU) admissions. This retrospective comparative study was conducted at Prince Mohammed bin Abdulaziz Hospital in Riyadh, Kingdom of Saudi Arabia (KSA), and assessed the impact of dyslipidemia and T2DM on COVID-19 severity and ICU admission. METHODOLOGY: A retrospective comparative study analyzed the data of 239 COVID-19 patients admitted to Prince Mohammed bin Abdulaziz Hospital in Riyadh between March and July 2020. The study assessed COVID-19 severity among patients with dyslipidemia and T2DM and the need for ICU admission. Data analysis employed odds ratios, Fisher's exact tests, and binary logistic regression using SPSS version 25 (IBM, SPSS, Chicago, IL, USA).
resultsThe findings revealed a very strong association between dyslipidemia and T2DM coexistence (adjusted OR (aOR) = 120.82, P = 0.001). Dyslipidemia significantly increased the risk of tachypnea (aOR = 58.263, P = 0.003), shortness of breath (SoB) (aOR = 10.729 (1.251-92.016), P = 0.003), and the likelihood of ICU admission, independently, as well as in the presence of T2DM (aOR = 8.136, P = 0.026). The results showed a significant association with abnormal high-density lipoprotein (HDL) cholesterol, triglycerides, and total cholesterol (P < 0.05). Fever is notably linked to dyslipidemia (P = 0.048). Among inflammatory markers, fibrinogen showed a very strong association with dyslipidemia in the presence of T2DM, in the context of the ICU setting (1,235 (10.021-152,261.746), P = 0.004). Similarly, chest X-ray (CXR) findings also showed significant association with dyslipidemia (P = 0.039).
conclusionThis study highlights the substantial impact of dyslipidemia, independently, as well as in the presence of T2DM, on ICU admission among COVID-19 patients in Riyadh, KSA. The findings emphasize the need for tailored care, early intervention, and optimized management of comorbid conditions. Proactive risk assessment in individuals with T2DM and dyslipidemia can reduce the probability of severe illness and ICU admission in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.